Ipamorelin

Overview

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) and the first selective ghrelin receptor agonist developed specifically to stimulate GH release with minimal off-target hormonal effects. Developed by Novo Nordisk in the late 1990s, ipamorelin activates the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor targeted by the endogenous hunger hormone ghrelin — to trigger pulsatile GH release from the anterior pituitary. Its defining characteristic is selectivity: unlike earlier GHRPs (GHRP-2, GHRP-6) which significantly elevate cortisol and ACTH alongside GH, ipamorelin produces robust GH release with no significant effect on cortisol, prolactin, ACTH, FSH, LH, or TSH — even at doses more than 200 times its effective GH-releasing dose. This clean selectivity profile makes it the most studied GHRP for combination protocols. Ipamorelin is not FDA approved and is classified as a research compound.

Mechanism of Action

1. GHS-R1a Receptor Agonism [1] — Ipamorelin binds to and activates the growth hormone secretagogue receptor type 1a (GHS-R1a) — a ghrelin-sensitive receptor located on somatotroph cells in the hypothalamus and anterior pituitary. This binding triggers G-protein activation through the Gαq/11 subunit.
2. Intracellular Calcium Signaling [1] — GHS-R1a activation by ipamorelin triggers the phospholipase C (PLC) pathway, hydrolyzing PIP2 into IP3 and diacylglycerol (DAG). IP3 facilitates calcium release from the endoplasmic reticulum while DAG activates protein kinase C — both converging on the secretory machinery of somatotrophs to trigger GH release.
3. Selective GH Release Without Cortisol Elevation [2] — A landmark pharmacological study established that ipamorelin produces GH release comparable to GHRP-6 in potency and efficacy, but crucially does not elevate ACTH or cortisol levels even at doses more than 200-fold higher than its GH-releasing ED50. This selectivity distinguishes it from all previous GHRPs.
4. Dual-Pathway Synergy with CJC-1295 [3] — Ipamorelin activates the GHS-R1a pathway while CJC-1295 activates the separate GHRH receptor pathway. Simultaneous activation of both produces supraadditive GH release — greater than the sum of either compound alone — through complementary intracellular signaling cascades.

Key Research Areas

1. Selectivity Profile — Landmark Pharmacology Study [2] — The definitive 1998 study published in European Journal of Endocrinology established ipamorelin as the first GHRP-receptor agonist with GH release selectivity comparable to GHRH itself — robust GH stimulation with no significant cortisol, ACTH, prolactin, FSH, LH, or TSH elevation.
2. GH Stack with CJC-1295 [3] — Combining ipamorelin with CJC-1295 represents the most researched GHRH+GHRP synergy pair. The combination produces amplified pulsatile GH output by simultaneously engaging both the GHRH receptor and ghrelin receptor pathways.
3. Body Composition and Metabolic Research [3] — GH elevation via ipamorelin stimulation promotes lean muscle synthesis, fat metabolism, improved sleep quality, and tissue repair through downstream IGF-1 signaling.

Observed Benefits in Research

1. Robust GH release comparable to GHRP-6 in potency and efficacy
2. No significant cortisol, ACTH, prolactin, FSH, LH, or TSH elevation — even at supraphysiological doses
3. Synergistic GH amplification when combined with CJC-1295
4. Physiologically relevant pulsatile GH release pattern
5. Potential improvements in body composition, recovery, and sleep via GH/IGF-1 axis

Pharmacokinetics

1. Structure: Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) — 5 amino acids
2. Half-life: Approximately 2 hours
3. Administration: Subcutaneous injection
4. Onset: Rapid GH release, typically within 15–30 minutes of injection

Research Limitations

Ipamorelin research carries important limitations: (1) The landmark selectivity data comes primarily from animal studies; comprehensive long-term human trial data is limited. (2) Long-term effects of sustained GH stimulation on pituitary function and downstream systems are not fully established. (3) Theoretical risks of chronic IGF-1 elevation include insulin resistance and mitogenic effects. (4) Ipamorelin is not FDA approved for any therapeutic use. (5) Prohibited by WADA in competitive sport.

Common Research Stacking

Ipamorelin is most commonly studied with CJC-1295 — the GH Stack — for synergistic dual-pathway GH stimulation. Also studied with IGF-1 LR3 for downstream anabolic amplification and BPC-157/TB-500 for broader recovery protocols.

References

1. IRE Journals. The Mechanism of Action and Synergy of CJC-1295 And Ipamorelin Peptide Blend. 2026. https://www.irejournals.com/paper-details/1714043
2. PubMed. Ipamorelin, the first selective growth hormone secretagogue. 1998. https://pubmed.ncbi.nlm.nih.gov/9849822/
3. Spartan Peptides. CJC-1295 and Ipamorelin: The Research-Backed Growth Hormone Peptide Blend. 2026. https://spartanpeptides.com/blog/cjc-1295-ipamorelin-complete-2026-research-guide/